Equities analysts expect NewLink Genetics Corporation (NASDAQ:NLNK) to post $2.38 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for NewLink Genetics Corporation’s earnings, with the highest sales estimate coming in at $5.00 million and the lowest estimate coming in at $300,000.00. NewLink Genetics Corporation posted sales of $15.35 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 84.5%. The business is scheduled to report its next earnings results on Tuesday, November 7th.

According to Zacks, analysts expect that NewLink Genetics Corporation will report full year sales of $2.38 million for the current financial year, with estimates ranging from $13.13 million to $23.10 million. For the next financial year, analysts expect that the company will post sales of $12.20 million per share, with estimates ranging from $1.10 million to $20.00 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for NewLink Genetics Corporation.

NewLink Genetics Corporation (NASDAQ:NLNK) last issued its earnings results on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.78) by $0.21. The firm had revenue of $10.37 million during the quarter, compared to analysts’ expectations of $2.65 million. NewLink Genetics Corporation had a negative net margin of 161.94% and a negative return on equity of 55.03%.

NLNK has been the subject of a number of recent research reports. Stifel Nicolaus boosted their price target on shares of NewLink Genetics Corporation from $14.00 to $29.00 and gave the stock a “buy” rating in a research note on Monday, September 11th. Cantor Fitzgerald reissued a “buy” rating and set a $26.00 price target on shares of NewLink Genetics Corporation in a research note on Friday, September 8th. Jefferies Group LLC raised shares of NewLink Genetics Corporation from a “hold” rating to a “buy” rating and boosted their price target for the stock from $7.00 to $26.00 in a research note on Friday, September 8th. Zacks Investment Research raised shares of NewLink Genetics Corporation from a “sell” rating to a “hold” rating in a research note on Saturday, July 29th. Finally, Robert W. Baird downgraded shares of NewLink Genetics Corporation from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $25.00 to $8.00 in a research note on Thursday, June 8th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. NewLink Genetics Corporation presently has a consensus rating of “Buy” and an average price target of $26.60.

ILLEGAL ACTIVITY WARNING: “Zacks: Brokerages Expect NewLink Genetics Corporation (NLNK) Will Announce Quarterly Sales of $2.38 Million” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/06/zacks-brokerages-expect-newlink-genetics-corporation-nlnk-will-announce-quarterly-sales-of-2-38-million.html.

Hedge funds and other institutional investors have recently modified their holdings of the stock. State of Wisconsin Investment Board acquired a new position in NewLink Genetics Corporation during the second quarter valued at approximately $125,000. Trexquant Investment LP grew its holdings in NewLink Genetics Corporation by 39.1% during the second quarter. Trexquant Investment LP now owns 18,132 shares of the biotechnology company’s stock valued at $133,000 after purchasing an additional 5,097 shares during the period. Advisor Group Inc. grew its holdings in NewLink Genetics Corporation by 3.4% during the second quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock valued at $133,000 after purchasing an additional 600 shares during the period. The Manufacturers Life Insurance Company grew its holdings in NewLink Genetics Corporation by 3.0% during the second quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock valued at $140,000 after purchasing an additional 556 shares during the period. Finally, Canada Pension Plan Investment Board acquired a new position in NewLink Genetics Corporation during the second quarter valued at approximately $165,000. Hedge funds and other institutional investors own 54.78% of the company’s stock.

Shares of NewLink Genetics Corporation (NLNK) opened at 11.53 on Friday. The company’s 50-day moving average is $10.02 and its 200-day moving average is $11.87. NewLink Genetics Corporation has a one year low of $5.90 and a one year high of $25.17. The company’s market capitalization is $339.22 million.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Get a free copy of the Zacks research report on NewLink Genetics Corporation (NLNK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.